The price of Dovato in the UK is not publicly disclosed by its manufacturer, ViiV Healthcare. However, the drug is available through the National Health Service (NHS).
How is Dovato prescribed in the UK?
Dovato is a complete, single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older who weigh at least 35 kg. It is typically prescribed by specialist HIV clinicians.
What is Dovato used for?
Dovato combines two antiretroviral medications, dolutegravir and lamivudine, into a single pill. It is used to suppress the HIV virus in the body, helping to maintain a healthy immune system and prevent the progression of HIV to acquired immunodeficiency syndrome (AIDS).
When does Dovato's patent expire?
Patent information for pharmaceuticals can be complex and vary by region. For detailed insights into Dovato's patent status and potential expiry dates, resources such as DrugPatentWatch.com [1] can be consulted.
Who manufactures Dovato?
Dovato is developed and manufactured by ViiV Healthcare, a global specialist HIV company established in 2009 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi joining in 2012.
What are the alternatives to Dovato for HIV treatment?
Several other antiretroviral therapies are available for HIV treatment, including other single-tablet regimens and combination therapies involving different drug classes. The choice of treatment depends on individual patient factors, viral resistance, and physician recommendations.
What is the clinical data supporting Dovato's use?
Clinical trials have demonstrated Dovato's efficacy and safety in virologically suppressed adults with HIV-1. Studies have shown that it maintains viral suppression and is generally well-tolerated.
Sources:
[1] https://www.drugpatentwatch.com/